ADMA Biologics (NASDAQ:ADMA) Stock Passes Above Fifty Day Moving Average – Here’s What Happened

Shares of ADMA Biologics Inc (NASDAQ:ADMA) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $8.96 and traded as high as $9.04. ADMA Biologics shares last traded at $8.72, with a volume of 3,583,362 shares trading hands.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Negative Sentiment: Multiple law firms announced or reminded investors about an active securities class action against ADMA Biologics, with an August 10, 2026 lead-plaintiff deadline. The complaints allege potential securities law violations tied to disclosures about revenues, internal controls, and alleged “channel stuffing” claims. Article: Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
• Negative Sentiment: Bleichmar Fonti & Auld said a class action was filed after ADMA’s shares previously dropped sharply following Culper Research channel-stuffing allegations, reinforcing concerns about possible accounting or sales-practices issues. Article: $ADMA Fraud Alert: ADMA Biologics Investors Sue for Recovery in Securities Fraud Class Action after 29% Stock Drop – Investors Notified to Contact BFA Law
• Neutral Sentiment: Several other firms, including Rosen, Schall, Gross Law Firm, Kahn Swick & Foti, Bragar Eagel & Squire, and others, issued similar notices encouraging affected shareholders to seek counsel, adding more noise around the stock but not changing the underlying business picture yet. Article: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price target for the company. Finally, Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Hold” and an average target price of $19.67.

ADMA Biologics Trading Up 0.3%

The company has a 50-day simple moving average of $8.93 and a 200-day simple moving average of $13.40. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The stock has a market cap of $2.03 billion, a P/E ratio of 12.86 and a beta of 0.72.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. The business’s revenue for the quarter was down .3% on a year-over-year basis. On average, sell-side analysts forecast that ADMA Biologics Inc will post 0.82 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman acquired 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director directly owned 513,884 shares in the company, valued at $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 3.90% of the stock is currently owned by corporate insiders.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently modified their holdings of ADMA. Summit Securities Group LLC acquired a new position in ADMA Biologics during the 4th quarter worth $29,000. Western Wealth Management LLC acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at $31,000. Clearstead Advisors LLC raised its position in shares of ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 795 shares during the last quarter. iSAM Funds UK Ltd bought a new stake in shares of ADMA Biologics during the third quarter worth $34,000. Finally, RiverPark Advisors LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at $35,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.